Stockscreener 앱 받기
202.73
2.50%
4.94
시간 외 거래:
202.73
Natera Inc 주식(NTRA)의 최신 뉴스
Groupama Asset Managment Has $12.42 Million Stock Holdings in Natera, Inc. $NTRA - MarketBeat
Jonathan Sheena files Rule 144 notice selling shares (NASDAQ: NTRA) - Stock Titan
Natera, Inc. (NTRA) reports preliminary Q4 revenue - MSN
Faithward Advisors LLC Invests $3.52 Million in Natera, Inc. $NTRA - MarketBeat
Livforsakringsbolaget Skandia Omsesidigt Buys 17,100 Shares of Natera, Inc. $NTRA - MarketBeat
JP Morgan lifts Natera, Inc. (NTRA) target on Signatera momentum - MSN
Insider Selling: Natera (NASDAQ:NTRA) Director Sells 122 Shares of Stock - MarketBeat
Natera director Chapman sells $23348 in shares - Investing.com
Natera director Chapman sells $23348 in shares By Investing.com - Investing.com Australia
Natera (NTRA) director sells 122 shares under 10b5-1 trading plan - Stock Titan
Natera Looks Compelling As Oncology Testing Momentum Keeps Building (NASDAQ:NTRA) - Seeking Alpha
Natera named Healthcare Technology Company of the Year - The Healthcare Technology Report.
Assessing Natera (NTRA) Valuation After New Signatera Data And Zenith Genomics Launch - simplywall.st
Holocene Advisors LP Decreases Stock Holdings in Natera, Inc. $NTRA - MarketBeat
Boothbay Fund Management LLC Increases Position in Natera, Inc. $NTRA - MarketBeat
Natera executive chairman sells $38.3 million in NTRA stock - Investing.com
Natera executive chairman sells $38.3 million in NTRA stock By Investing.com - Investing.com Canada
NeoGenomics, Natera, and Amphastar Pharmaceuticals Stocks Soar—Key Information You Should Be Aware Of - Bitget
NeoGenomics, Natera, and Amphastar Pharmaceuticals Shares Skyrocket, What You Need To Know - Yahoo Finance
Natera (NTRA) chair Rabinowitz exercises options and sells 200,000 shares - Stock Titan
NeoGenomics, Natera, and Amphastar Pharmaceuticals shares skyrocket, what you need to know - MSN
Why Natera Stock Is Surging On Fresh Optimism - TipRanks
NTRA Debuts Zenith Genomics Next-Gen Sequencing Test for Rare Diseases - Yahoo Finance
Natera (NTRA) Highlights Promising Results for Signatera in Canc - GuruFocus
Natera ctDNA test shows promise in anal, rectal cancer studies - Investing.com
Natera ctDNA test shows promise in anal, rectal cancer studies By Investing.com - Investing.com India
Fred Alger Management LLC Buys 41,303 Shares of Natera, Inc. $NTRA - MarketBeat
Farallon Capital Management LLC Sells 568,357 Shares of Natera, Inc. $NTRA - MarketBeat
Cancer DNA test ties anal and rectal tumors to relapse odds - Stock Titan
Natera launches whole genome sequencing test for rare diseases - Investing.com Nigeria
Coatue Management LLC Takes Position in Natera, Inc. $NTRA - MarketBeat
Capital Impact Advisors LLC Boosts Stock Position in Natera, Inc. $NTRA - MarketBeat
Aquatic Capital Management LLC Increases Position in Natera, Inc. $NTRA - MarketBeat
Pinnbrook Capital Management LP Makes New $5.78 Million Investment in Natera, Inc. $NTRA - MarketBeat
Guidance Update: Can Natera Inc keep up with sector leadersPortfolio Gains Summary & AI Based Trade Execution Alerts - baoquankhu1.vn
[144] Natera, Inc. SEC Filing - Stock Titan
Natera Launches Zenith Genomics To Expand Rare Disease Testing Story - simplywall.st
Zenith Genomics Launch Could Be A Game Changer For Natera’s (NTRA) Rare Disease Strategy - Yahoo Finance
Meridiem Capital Partners LP Invests $11.90 Million in Natera, Inc. $NTRA - MarketBeat
Quantitative Investment Management LLC Acquires 6,152 Shares of Natera, Inc. $NTRA - MarketBeat
16,650 Shares in Natera, Inc. $NTRA Purchased by Magnetar Financial LLC - MarketBeat
Korea Investment CORP Cuts Position in Natera, Inc. $NTRA - MarketBeat
MyOme Debuts Zenith™ Portfolio with Natera and Launches Long-Read Methylation Analysis at ACMG 2026 - Sahm
MyOme Debuts Zenithtm Portfolio with Natera and Launches Long-Read Methylation Analysis at ACMG 2026 - lelezard.com
GeneDx stock falls as Natera launches competing rare disease test - Investing.com UK
GeneDx stock falls as Natera launches competing rare disease test By Investing.com - Investing.com Australia
Natera announces commercial launch of Zenith genomics - TipRanks
Natera Announces Commercial Launch of Zenith™ Genomics for Rare Disease Diagnosis - BioSpace
MyOme Debuts Zenith Portfolio with Natera and Launches Long-Read Methylation Analysis at ACMG 2026 - Finviz
Natera, Inc. $NTRA Shares Sold by Swiss National Bank - MarketBeat
New genome test from Natera and MyOme targets 5-year rare disease delays - Stock Titan
Natera, Inc. $NTRA Shares Bought by Franklin Resources Inc. - MarketBeat
Capital Fund Management S.A. Buys 41,307 Shares of Natera, Inc. $NTRA - MarketBeat
Natera director Sheena Jonathan sells $25924 in stock - Investing.com Australia
Natera president Fesko sells $144k in shares By Investing.com - Investing.com Canada
Natera: Daniel Rabinowitz sells $356k in shares - Investing.com
Natera president Fesko sells $144k in shares - Investing.com
Natera director Sheena Jonathan sells $25924 in stock By Investing.com - Investing.com India
Natera: Daniel Rabinowitz sells $356k in shares By Investing.com - Investing.com India
Insider Selling: Natera (NASDAQ:NTRA) CEO Sells 5,623 Shares of Stock - MarketBeat
1.53%
0.33%
자본화:
|
볼륨(24시간):